查詢結果分析
來源資料
相關文獻
- Small Cell Carcinoma of Uterine Cervix: A Single-institution Experience
- 延展照野放射線治療在剖腹術後子宮頸癌之效果分析
- Experiences of Radiotherapy on Extrapulmonary Small Cell Carcinoma
- Comparison of Weekly Vinorelbine and Weekly Docetaxel, Each with Cisplatin, for Locally Advanced Non-small Cell Lung Cancer in Patients with Concurrent Chemoradiotherapy
- Brain Metastasis from Small Cell Cervical Carcinoma with Long-Term Survival--A Case Report
- 非小細胞癌肺部放射治療計畫之探討
- Limited-Stage Small Cell Carcinoma of Esophagus: A Single Institution Experience
- Small Cell Carcinoma of the Duodenum: A Case Report
- Small Cell Carcinoma of External Auditory Canal: A Case Report
- Primary Small Cell Carcinoma of the Esophagus: Two Case Reports
頁籤選單縮合
題 名 | Small Cell Carcinoma of Uterine Cervix: A Single-institution Experience=子宮頸小細胞癌:單一機構之經驗 |
---|---|
作 者 | 林逢嘉; 王令瑋; 林立青; 郭珍妮; 顏上惠; | 書刊名 | 中華放射線醫學雜誌 |
卷 期 | 31:1 民95.02 |
頁 次 | 頁15-20 |
分類號 | 417.2832 |
關鍵詞 | 放射治療; 小細胞癌; 子宮腫瘤; Radiotherapy; Small cell carcinoma; Uterine neoplasm; |
語 文 | 英文(English) |
中文摘要 | 為了解子宮頸小細胞癌的治療效果,我們回顧台北榮民總醫院從一九九三年至二○○一年間的子宮頸小細胞癌病例,分析病患各項人口學特徵及臨床相關資料,以Kaplan-Meier method 計算病患存活狀況,以log-rank test 來確認統計上的顯著差異。 子宮頸小細胞癌占該醫院同時期子宮頸惡性腫瘤的0.38% 。本研究共含括九位病人,他們的年齡中位數為45 歲 (32-77 歲),陰道出血為所有病患的主要表現病徵,診斷前病徵持續時間為3個月 (1-6 個月)。在9位病患的臨床期別中,3位IB 、2位IIA 、1位IIB 、2位IIIB 及1位IVB 。關於治療方面,5位病患接受根除性手術及化學治療,2位接受根除性手術、化學治療及放射治療,1位接受化學治療及放射治療,1位接受化學治療。在追蹤28 個月後,5位病患無病存活,3位因小細胞癌死亡,1位因非腫瘤疾病死亡;病患的中位存活時間仍未達到,五年存活率為66.67% 。早期疾病的病患存活期較晚期者長,但停經前及停經後病患的存活狀況則沒有顯著差異。總之,子宮頸小細胞癌是一種少見的高度惡性腫瘤,容易轉移;早期疾病的病患有較好的預後,必須使用多科整合的治療方可達到最佳效果。 |
英文摘要 | We aimed to analyze the clinical outcome of patients with small cell carcinoma (SmCC) of uterine cervix. We retrospectively reviewed the clinical courses of patients with SmCC of uterine cervix referred to Taipei Veterans General Hospital between 1993 and 2001. Demographic and clinical data were presented and analyzed. Survival analysis was performed by using the Kaplan-Meier method. The statistical significance was determined by the log-rank test. SmCC represented 0.38% of malignancies of uterine cervix in this institution. Nine patients with SmCC of uterine cervix were included in this study. The median age at diagnosis was 45 years (range, 32-77 years) . Vaginal bleeding was the most common symptom presented in all our patients. The median duration of the symptoms before diagnosis was 3 months (range, 1-6 months) . Three patients were stage IB, two IIA, one IIB, two IIIB, and one IVB by FIGO staging at diagnosis. Five patients underwent radical surgery and adjuvant chemotherapy; two, radical surgery, adjuvant chemotherapy and radiotherapy; one, chemotherapy and radiotherapy; and one, chemotherapy only. With a median follow-up of 28 months, three patients died of this disease, five patients remained alive without disease and the remaining one patient died of a non-cancer related cause. The median overall survival (OS) was not reached and the estimated 5-year survival rate was 66.67%. The median OS was significantly longer in patients with early stage disease (P = 0.02) . There was no significant difference in median OS between pre-menopausal and menopausal patients (P = 0.466) . In summary, SmCC of uterine cervix is a relatively rare but aggressive neoplasm with high potential of metastases. Patients with early stage disease had better prognosis. Combined-modality treatment is necessary to achieve the optimal outcome. |
本系統中英文摘要資訊取自各篇刊載內容。